<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>sofosbuvir &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/sofosbuvir/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 10 Oct 2026 06:09:58 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>sofosbuvir &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Hepatitis C Cure Rates Hit 96% in Yemen with a Single Antiviral Regimen</title>
		<link>https://bioengineer.org/hepatitis-c-cure-rates-hit-96-in-yemen-with-a-single-antiviral-regimen/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 10 Oct 2026 06:09:58 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[anemia]]></category>
		<category><![CDATA[BMC Infectious Diseases]]></category>
		<category><![CDATA[direct-acting antivirals]]></category>
		<category><![CDATA[hepatitis C]]></category>
		<category><![CDATA[hepatitis C virus]]></category>
		<category><![CDATA[ledipasvir]]></category>
		<category><![CDATA[pegylated interferon]]></category>
		<category><![CDATA[Resource-limited settings]]></category>
		<category><![CDATA[ribavirin]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[sustained virologic response]]></category>
		<category><![CDATA[Yemen]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=412148</guid>

					<description><![CDATA[A retrospective cohort study in Yemen found that a twelve-week course of ledipasvir/sofosbuvir plus ribavirin cured 96 percent of treatment-naïve and 94 percent of previously treated chronic hepatitis C patients, with no significant difference between the groups.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">412148</post-id>	</item>
	</channel>
</rss>
